Advanced Tissue Sciences gathering additional Dermagraft data; PMA submission on target for December.
This article was originally published in The Gray Sheet
Executive Summary
ADVANCED TISSUE SCIENCES GATHERING DERMAGRAFT DATA ON 20-30 MORE PATIENTS for use of the bioengineered skin replacement in the treatment of diabetic foot ulcers. The company is gathering the data at FDA's request to demonstrate that a version of the product that will be produced commercially is clinically equivalent to the product used in a pivotal clinical study that was produced by a pilot manufacturing process. The only obvious difference between the two is size: the commercial product will measure 2" x 3" while the size used in clinicals measured 4" x 6", ATS says.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.